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TLR and complement activation ensures efficient clearance of infection. Previous studies
documented synergism between TLRs and the receptor for the pro-inflammatory comple-
ment peptide C5a (C5aR/CD88), and regulation of TLR-induced pro-inflammatory responses
by C5aR, suggesting crosstalk between TLRs and C5aR. However, it is unclear whether and
how TLRs modulate C5a-induced pro-inflammatory responses. We demonstrate a marked
positive modulatory effect of TLR activation on cell sensitivity to C5a in vitro and ex vivo and
identify an underlying mechanistic target. Pre-exposure of PBMCs and whole blood to
diverse TLR ligands or bacteria enhanced C5a-induced pro-inflammatory responses. This
effect was not observed in TLR4 signalling-deficient mice. TLR-induced hypersensitivity to
C5a did not result from C5aR upregulation or modulation of C5a-induced Ca21mobilization.
Rather, TLRs targeted another C5a receptor, C5L2 (acting as a negative modulator of C5aR),
by reducing C5L2 activity. TLR-induced hypersensitivity to C5a was mimicked by blocking
C5L2 and was not observed in C5L2KO mice. Furthermore, TLR activation inhibited C5L2
expression upon C5a stimulation. These findings identify a novel pathway of crosstalk
within the innate immune system that amplifies innate host defense at the TLR-comple-
ment interface. Unravelling the mutually regulated activities of TLRs and complement may
reveal new therapeutic avenues to control inflammation.
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Introduction
The innate immune system plays a crucial role in the inflamma-
tory response to infection through the activity of receptors
capable of recognizing defined molecular patterns present in a
variety of microorganisms. In particular, the concerted activity of
two components of the innate immune system, TLRs and
complement, results in rapid inflammatory responses and also
orchestrates adaptive immune responses that lead to clearance of
infection [1–4].
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TLRs are critical to the triggering of the inflammatory
response. They recognize and respond to an array of
microorganisms and their components, many of which can also
activate complement, by mediating a prompt and efficient pro-
inflammatory response [1, 5]. This includes the production of a
variety of inflammatory mediators, e.g. IL-6, TNF-a, IL-8
(CXCL8), MCP-1 (CCL2), resulting in an immediate response to
the microbial challenge. However, the excessive release of pro-
inflammatory molecules as a consequence of TLR hyperactivation
can lead to serious pathological conditions such as acute
inflammation, tissue/organ damage, septic shock, chronic
inflammation and autoimmunity [6, 7].
Microorganisms and their components also activate the
complement system, which plays a significant role in acute
inflammation and the destruction of invading microorganisms.
Complement activation leads to the generation of biologically
active complement peptide fragments such as C5a and C3a that
elicit a number of pro-inflammatory effects [2, 8]. The comple-
ment anaphylatoxin C5a in particular is one of the most potent
pro-inflammatory peptides. It acts as a granulocyte, monocyte
and macrophage chemoattractant. It is a vasodilator, induces the
oxidative burst in neutrophils and enhances phagocytosis, gran-
ule enzyme release and adhesion molecule expression. It acti-
vates the coagulation cascade, induces the synthesis and release
of arachidonic acid metabolites as well as pro-inflammatory
cytokines and chemokines. Excessive generation of C5a, however,
contributes to serious inflammatory conditions such as sepsis
[9, 10]. C5a exerts most of its effects through the C5a receptor
(C5aR), a seven-transmembrane G protein-coupled receptor.
Recently, the involvement of a second seven-transmembrane, but
G protein-uncoupled, receptor for C5a, C5L2, in the biological
activities of C5a and as a negative modulator of C5aR activity has
been reported [11–13].
Given the serious acute and chronic inflammatory conditions
resulting from over-activation or dysregulation of TLR-mediated
responses and/or excessive C5a-induced pro-inflammatory
responses, TLR and C5a receptor signalling are attractive ther-
apeutic targets for the treatment and/or prevention of inflam-
matory conditions [7, 9, 14–16]. Therefore, understanding the
mechanisms modulating TLR activity and the C5a-C5a receptor
interaction is of major interest.
Notably, it has previously been shown that cell exposure to a
combination of LPS and C5a resulted in enhanced production of a
number of cytokines and chemokines, indicating synergism
between TLRs and C5aR [17–19]. Furthermore, C5a-triggered
signalling through C5aR substantially enhanced or modulated
microbial-induced pro-inflammatory cytokine production medi-
ated by TLRs [20, 21]. A negative effect of C5aR engagement on
the TLR4-mediated production of the IL-12 family of immuno-
modulatory cytokines has also been reported [22], and recently it
has been demonstrated that Porphyromonas gingivalis-generated
C5a enhancement of TLR2-mediated cyclic AMP production
results in macrophage immunosuppression [23]. Thus, through
the C5a–C5aR interaction, complement appears to influence
the extent of the pro-inflammatory and immunomodulatory
responses triggered via TLRs. Together, these findings provided
evidence for crosstalk between the complement system and TLRs,
strengthening the innate host defense during infection [3, 4].
However, most studies have focused on the immunoregulatory
effect of C5a on TLR-driven inflammation, neglecting potential
effects of TLR activation on complement-mediated inflammation.
In the present study, we have therefore evaluated the impact of
TLR activation on C5a-driven cytokine and chemokine produc-
tion in vitro and ex vivo. Our data demonstrate a marked positive
modulatory effect of TLR activation on cell sensitivity to C5a,
supporting the concept of a genuine crosstalk between TLRs and
C5aR, and indicate that TLRs may exert their modulatory effect
by reducing the negative regulatory capacity of C5L2 on C5aR.
Results
PBMCs pre-exposed to TLR ligands are hypersensitive
to C5a stimulation
To evaluate a potential modulatory effect of TLRs on C5a-mediated
pro-inflammatory responses, PBMCs were first stimulated with TLR
ligands. Following extensive washing, the cells were stimulated
with C5a before assessment of IL-8 levels in the cell culture
supernatants. Figure 1A shows that the levels of IL-8 released by
C5a-stimulated PBMCs pre-exposed to the TLR4 ligand, LPS, were
substantially higher than those released by cells not pre-exposed to
LPS. Similarly, a two- to ten-fold increase in the C5a-induced
release of IL-8 was observed when PBMCs were pre-exposed to
ligands for TLR2/TLR1, TLR2/TLR6 (the synthetic bacterial
lipopeptide, Pam3-Cys-Ser-Lys4 and yeast zymosan respectively),
TLR5 (bacterial flagellin) and TLR7/TLR8 (the antiviral compound,
imiquimod), the extent of the increase depending on the TLR
ligand and the C5a concentration tested (Fig. 1B). TLR-induced
hypersensitivity to C5a was observed following pre-exposure to a
wide range of TLR ligand concentrations, as is shown in Fig. 1C in
the case of LPS. Here, even pre-exposure to 10pg/mL LPS, a
concentration well below those found in sepsis patients (100pg/
mL to 700pg/mL, [24]), resulted in hypersensitivity to C5a.
Together, these findings indicated that TLR activation imparts
hypersensitivity to blood mononuclear cells to C5a.
TLR-induced hypersensitivity to C5a was not restricted to the
release of IL-8, as the release of the pro-inflammatory cytokine,
IL-6, was similarly enhanced (Fig. 1D). Furthermore, PBMC pre-
exposure to TLR ligands not only affected the C5a-induced
release but also the transcription of pro-inflammatory mediators,
since mRNA levels for both IL-6 and IL-8 markedly increased
(Fig. 1E). Consistent with this finding, the activation levels of the
transcription factor NF-kB – a key regulator of immunoregulatory
gene transcription – in nuclear extracts of C5a-stimulated PBMCs
that were pre-exposed to LPS were substantially higher than
those in cells not pre-exposed (Fig. 1F). This finding also indi-
cated that TLR modulation of cell sensitivity to C5a has a wide
spectrum of activities and, thus, a wide range of pro-inflamma-
tory and immunomodulatory mediators might be affected.
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Figure 1. Sensitivity to C5a of PBMCs pre-exposed to TLR ligands. (A–C) Levels of IL-8 in culture supernatants of PBMCs (1.5 105/well)
(A) stimulated for 14 h with the indicated concentrations of C5a and (B) after washing and re-culture following pre-exposure (14 h) to LPS (100 pg/
mL or as indicated), Pam3Cys (100 ng/mL), Zymosan (1 mg/mL), Flagellin (5 mg/mL), Imiquimod (3 mg/mL) or mock-pre-exposure (no TLR ligand). IL-8
concentrations were estimated by subtracting the background levels of IL-8 present in cultures not activated with C5a and pre-exposed or not to
TLR ligands from the corresponding C5a-activated samples (IL-8 background levels (ng/mL): No ligand/No C5a, 1.670.7; 1LPS, 2.371.2; 1Pam3Cys,
1.570.6; 1Zymosan, 1.370.9; 1Flagellin, 6.972.5; 1Imiquimod, 5.371.1; nZ4). (C) IL-8 fold increases were determined by comparing IL-8 levels –
after background subtraction – between C5a-stimulated (10 nM) cell samples pre-exposed and not pre-exposed to LPS. (D) Levels of IL-6 in culture
supernatants of PBMCs stimulated for 14 h with the indicated concentrations of C5a, after washing and re-culture following pre-exposure to LPS.
(E and F) Determination of (E) IL-6 and IL-8 mRNA levels in RNA samples and (F) NF-kB concentrations in the nuclear extracts of PBMCs pre-
exposed or not to LPS and subsequently stimulated with C5a as described for A–D. (E) mRNA levels are relative to control (No LPS/No C5a). Results
are from one experiment (1SD) representative of at least four for each ligand (A, B) or three (C–F). po0.05, po0.01, po0.005 (TLR-pre-exposed
versus TLR not pre-exposed, paired Student’s t-test).
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Whole blood pre-exposure to LPS or Escherichia coli
increases blood cell sensitivity to C5a
To better evaluate the in vivo relevance of the positive modulatory
effect of TLR activation on cell sensitivity to C5a, we used a
minimally perturbed experimental model in which human whole
blood was pre-exposed to LPS or whole E. coli. Following washing,
the blood cells were resuspended in autologous plasma and
stimulated with varying concentrations of C5a. Pre-exposure of
whole blood to LPS or whole bacteria resulted in a substantially
higher sensitivity of blood cells to C5a stimulation (Fig. 2A),
suggesting that TLR modulation of peripheral blood immunocom-
petent cell sensitivity to C5a might occur in vivo. Analysis of the
modulatory effect over a wide range of C5a concentrations in 15
blood donors showed that the extent of the increase in cell
sensitivity to C5a depended on both the donor and the concentra-
tion of C5a tested (Fig. 2B), with 13 out of the 15 donors showing
a decline in their response to TLR activation (lower hypersensi-
tivity to C5a) at relatively high C5a concentrations.
LPS-induced enhanced blood cell sensitivity to C5a is
not observed in TLR4 signalling-deficient mice
To demonstrate that microbial-induced cell hypersensitivity
to C5a strictly depended on TLR activation, we compared
blood cell sensitivity to C5a ex vivo between mice deficient
in TLR4 signalling (C3H/HeJ) and WT (C3H/HeN) mice
that had been challenged with LPS (Fig. 3). The C5a-induced
release of the prototypical polymorphonuclear and
mononuclear cell chemoattractants keratinocyte-derived
chemokine (KC, a murine functional counterpart of human
IL-8) and MCP-1 (CCL2), respectively, was extremely low
in both TLR4-deficient and WT mice that had not been
previously challenged with LPS. However, pre-exposure
to LPS resulted in a markedly higher blood cell sensitivity to
C5a in WT, but not in TLR4-deficient mice (Fig. 3), thus
confirming the crucial role that TLR activation plays in this
phenomenon and supporting the in vivo relevance of the
modulatory effect of TLRs.
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Figure 2. Sensitivity to C5a of human blood cells pre-exposed to LPS or E. coli. (A) C5a-induced levels of IL-8 and (B) fold increase in IL-8
concentration in blood cell culture supernatants following whole blood (100 mL/well) pre-exposure or not to LPS (500 pg/mL, A, left and B) or E. coli
(1 108 CFU/mL). Pre-exposure to TLR ligands followed by C5a stimulation, and estimation of C5a-induced IL-8 concentrations and fold increases
were as described for Fig. 1. (A) Results are from one experiment (1SD) representative of three. po0.05, po0.005 (LPS- or E. coli-treated versus
mock-treated, paired Student’s t-test). (B) Response profile of 15 healthy blood donors.
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Figure 3. Ex vivo blood cell sensitivity to C5a of TLR4 signalling-deficient and WT mice. KC and MCP-1 levels in blood cell culture supernatants
(100 mL whole blood/condition) of C3H/HeJ and C3H/HeN (WT) mice stimulated (14 h) ex vivo with C5a following a challenge (1 h) i.p. with LPS (50 mg/
mouse) or PBS (no LPS). The C5a-induced chemokine concentrations were estimated by background subtraction as described for Fig. 1. Values are
expressed as the mean1SEM (n5 5/condition).po0.05, po0.01, po0.005 (LPS-treated versus no LPS, paired Student’s t-test).
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Pre-exposure to LPS downregulates C5aR expression
The positive modulation exerted by TLRs posed the question of
the underlying mechanism. The TLR modulatory effect appears to
be relatively rapid, as a 30-min pre-exposure to LPS was sufficient
to achieve maximal hypersensitivity to C5a (Fig. 4A). We then
tested whether TLRs modulate cell sensitivity to C5a by
upregulating C5aR expression. Given that monocytes are the
main TLR-expressing cell type in leukocytes [25], the main target
for C5a in PBMCs, and that they orchestrate many of the TLR-
induced responses of peripheral blood leukocytes, including those
of neutrophils [25], we focused on monocyte C5aR and
monitored its expression in PBMCs after a 30-min pre-exposure
to LPS. Subsequently, we continued monitoring C5aR expression
following stimulation with C5a. Monocyte C5aR cell-surface
expression was markedly lower in PBMCs pre-exposed to LPS
(Fig. 4B, left, 1LPS/No C5a versus No LPS/No C5a). After
3 h of C5a stimulation, both LPS-treated and untreated mono-
cytes showed lower cell-surface levels of C5aR than those at time
0. By 12 h post-C5a stimulation, C5aR levels had partially
recovered. This modulation pattern of C5aR expression following
C5a stimulation most likely reflects C5a-induced receptor
internalization and its recycling back to the cell surface, as
previously described [26–28]. In parallel experiments, we
confirmed that PBMCs from the same donors showed hypersen-
sitivity to C5a (IL-8 (ng/mL): No LPS/No C5a, 0.970.3; No LPS/
1C5a, 3.271.1; 1LPS/No C5a, 1.970.4; 1LPS/1C5a,
16.973.5; n53). The LPS-induced downmodulation of C5aR
cell-surface expression correlated with the determinations of
C5aR mRNA expression in PBMC aliquots collected from the
experiment described above at the end of the culture (12 h).
Indeed, pre-exposure to LPS – irrespective of C5a stimulation –
resulted in reduction in C5aR mRNA levels (Fig. 4C), thus
indicating that the LPS-induced C5aR downmodulation is exerted
at transcriptional level. Of note, TLR activation of whole blood
also resulted in negative modulation of neutrophil C5aR
expression (Fig. 4B, inset). Together, these findings indicated
that increased cell sensitivity to C5a following TLR activation is
not due to C5aR upregulation.
TLR activation induces cell hypersensitivity to C5a
without affecting C5a-induced Ca21 mobilization
Next, we tested whether the TLR modulatory effect extended to
C5a-mediated intracellular Ca21 mobilization, which depends on
G-protein coupling to C5aR [29]. PBMCs were pre-exposed to
LPS for 3min, 30min or 14 h, or left untreated, loaded with a
Ca21-chelating fluorescent dye, stimulated with C5a and moni-
tored over 3min for changes in cell fluorescence as a measure of
intracellular Ca21 mobilization (Fig. 5). Following C5a stimula-
tion, cells pre-exposed or not to LPS for any of the indicated
periods of time showed similar Ca21 increases (kinetics and
intensity). Similar results (not shown) were obtained following
cell pre-exposure to a ligand for TLR2 (Pam3-Cys-Ser-Lys4), a TLR
documented to induce Ca21 mobilization, unlike TLR4 [30].
These findings suggested that TLRs exert positive modulation on
cell sensitivity to C5a by affecting a G protein-dependent event
separate from Ca21 mobilization or a G protein-independent
signalling pathway used by C5aR.
TLR activation reduces C5L2 receptor activity and
expression
Seven-transmembrane receptors, like those for C5a, also signal
through a G-protein-independent pathway that involves the
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Figure 4. Effect of a pre-exposure to LPS on cell sensitivity to C5a and
C5aR expression. (A) Fold increase in the levels of IL-8 – determined as
described for Fig. 1– in culture supernatants of PBMCs (1.5 105/well)
pre-exposed or not to LPS (100 pg/mL) for the indicated times
(starting from 30 min), and subsequently activated (14 h) with C5a
(10 nM). (B) C5aR cell-surface expression levels on gated monocytes or
neutrophils (inset) at different times following 1106 PBMC (mono-
cytes) or 100 mL whole blood (neutrophils) pre-exposure (30 min)
to 100 pg/mL (PBMCs) or 500 pg/mL (whole blood) LPS or a mock-
pre-exposure (no LPS), and subsequent activation or not with C5a
(10 nM) for the indicated times. (C) C5aR mRNA levels determined by
RT-qPCR in RNA samples extracted from PBMC aliquots taken
from the experiment described in (B) at the end of the culture (12 h).
Results are from one experiment (A and C, 7SD) representative of
three. po0.05, po0.005 (LPS-pre-exposed versus not pre-exposed,
paired Student’s t-test).
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activity of b-arrestins – multifunctional adapter proteins that
mediate signalling and also control receptor desensitization and
trafficking [13, 31, 32]. Notably, C5aR signalling through the
b-arrestin pathway was reported to be negatively modulated by
the G protein-uncoupled C5a receptor, C5L2 [13]. Thus, to
evaluate the possibility that a C5a-triggered G-protein-indepen-
dent signalling event was the target of TLR modulation, we tested
the effect of TLR activation on the activity of C5L2. PBMCs were
pre-exposed to LPS and subsequently stimulated with C5a.
Following stimulation, the cell culture supernatants were tested
for IL-8 levels, and cytoplasmic cell extracts for levels of high-
mobility group box-1 protein (HMGB1). HMGB1 is a nuclear
factor that acts as a mediator of inflammation and sepsis whose
cytoplasmic mobilization and release upon C5a stimulation
depends on C5L2, but not C5aR [11, 33, 34] (Fig. 6A). Cell
pre-exposure to LPS resulted in relatively lower levels of C5a-
induced HMGB1 (Fig. 6A, 1LPS/1C5a versus No LPS/1C5a),
suggesting that TLR activation negatively affects C5L2 activity.
This was in contrast to the positive modulatory effect exerted by
TLRs on the C5aR-mediated pro-inflammatory responses
described above and confirmed in this experiment, as the culture
supernatants of PBMCs pre-exposed to LPS showed substantially
higher levels of IL-8 upon C5a stimulation (Fig. 6A, inset).
Further support for the role of TLRs as negative modulators of
C5L2 activity was obtained from the comparative analysis of
HMGB1 levels in blood cell culture supernatants between TLR4
signalling deficient and WT mice stimulated with C5a after LPS
challenge in vivo. Indeed, the level of C5a-induced HMGB1
released by blood cells of WT mice exposed to LPS was lower than
that of WT animals that were not exposed to LPS (Fig. 6B, C3H/
WT, 1LPS/1C5a versus No LPS/1C5a), whereas TLR4 signal-
ling-deficient mice did not show these differences.
The results of C5L2 receptor blocking experiments were also
consistent with the concept that the second C5a receptor is a
target of TLR modulation. C5a stimulation of PBMCs in the
presence of an anti-C5L2 blocking mAb showed a marked
reduction in HMGB1 levels (Fig. 7A, left). By contrast, the culture
supernatants of the C5L2 mAb-treated PBMCs showed higher
levels of IL-8 (Fig. 7A, right). These findings confirmed previous
observations on the effect of C5L2 receptor blockade on HMGB1
and cytokine production [11]. Notably, the effects of C5L2
blockade were similar to those resulting from cell pre-exposure to
LPS shown above (Fig. 6A), suggesting that the positive effect of
TLRs on C5a-induced responses may involve inhibition of C5L2
activity. To test this possibility further, we compared blood cell
sensitivity to C5a ex vivo between C5L2-deficient (C5L2KO) and
WT mice that had been challenged with LPS (Fig. 7B). The C5a-
induced release of KC was extremely low in both WT and C5L2KO
mice not challenged with LPS. Pre-exposure to LPS resulted in a
marked increase in cell sensitivity to C5a in WT but not in
C5L2KO mice, indicating that C5L2 is involved in the TLR
modulatory effect.
To explore the mechanism by which TLRs modulate C5L2
receptor activity, the C5L2 expression levels in cell lysates of
human PBMCs pre-exposed or not to LPS and stimulated with
C5a were compared (Fig. 7C). Following C5a stimulation, C5L2
levels were slightly increased. However, cell pre-exposure to LPS
before C5a stimulation resulted in a marked reduction in C5L2
expression in a LPS dose-dependent manner, indicating that TLR
activation negatively modulates C5L2 activity, at least in part, by
reducing C5L2 expression. It is noteworthy, however, that this
inhibitory effect of LPS occurs only upon subsequent C5a
stimulation.
Discussion
TLRs and the complement system play major roles in the innate
immune response against microbial pathogens. Their activation
triggers potent pro-inflammatory responses and microbial killing
mechanisms that ensure a prompt and efficient clearance of
infection. A mutually regulated and concerted activity of these
two innate immune components would strengthen the efficiency
of innate host defense. In support of this possibility, synergistic
effects between TLRs and C5aR, and a strong regulation of TLR-
mediated pro-inflammatory and immunoregulatory responses by
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Figure 5. C5a-induced Ca21 mobilization following PBMCs pre-expo-
sure to LPS. C5a (10 nM)-induced changes in monocyte cell fluores-
cence over 180 s, as a measure of intracellular Ca21 mobilization,
detected by flow cytometry following PBMC (1106/condition) pre-
exposure or not to LPS (100 pg/mL) for the indicated times and staining
with the Ca21-chelating fluorescent dye, Fluo3-AM. Background
fluorescence was determined before addition of C5a (time 0) in cells
pre-exposed or not to LPS. Results are expressed as normalized (Ca21)i:
the ratio between the mean fluorescence intensity at time t after C5a
addition and that at time 0. A representative experiment out of four is
shown.
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complement receptors have been reported [17–23]. These
findings suggested crosstalk between TLRs and complement
receptors [3, 4, 11, 20–23]. However, the putative modulatory
effect exerted by TLRs on complement receptor-mediated pro-
inflammatory responses and the underlying mechanism have not
been directly investigated. In this study, we focused on the
interaction of the complement anaphylatoxin C5a with its
receptors, C5aR and C5L2, and demonstrated that TLR activation
exerts substantial positive modulation on C5a-induced pro-
inflammatory cell responses to microbial components and whole
bacteria in vitro and ex vivo. Furthermore, we presented evidence
indicating that TLR modulates C5a-induced responses by
negatively modulating the activity of the second C5a receptor,
C5L2, which itself can act as a negative modulator of C5aR-
mediated responses [11, 13, 26–29]. This negative effect on C5L2
involves reduction of C5L2 receptor expression. These findings
indicate the existence of genuine crosstalk between TLRs and
complement that involves C5L2 and that the positive modulation
of C5a-induced pro-inflammatory responses by TLR activation is
a physiological feature that contributes to the prompt and
efficient innate immune response against microbial pathogens.
The modulatory capacity of TLRs does not appear to be
restricted by the nature of the pathogen, as we demonstrated that
ligands activating a variety of TLRs are capable of inducing
hypersensitivity to C5a. Notably, pre-exposure to a wide range of
TLR ligand concentrations, even to concentrations well below
those found in sepsis patients, resulted in enhanced responses to
C5a (Fig. 1C). This finding indicates that TLR modulation of cell
responses to C5a is an extremely sensitive mechanism that might
operate during the course of mild as well as severe infections.
However, TLR positive modulatory activity appears to be tightly
controlled, as it was accompanied by a marked TLR-induced
downregulation of C5aR expression and reduced C5a-induced
mobilization of the late mediator of inflammation, HMGB1. This
latter effect most likely resulted from the negative effect of TLR
activation on C5L2 – previously demonstrated to be the receptor
for C5a that mediates release of HMGB1 [11]. Of note, increased
levels of HMGB1 were observed in the culture supernatants from
blood cells of C3H/HeJ mice exposed to LPS that were not
stimulated with C5a ex vivo (Fig. 6B, C3H/HeJ, 1LPS/No C5a).
The lack of the postulated negative modulation of C5L2
activity by TLR4 activation in these mice may have led to the
observed increase in HMGB1, which most likely was generated
as a consequence of LPS-induced complement activation
in vivo and the resulting generation of C5a, which leads
to C5L2-mediated induction and late release of HMGB1. This
DNA-binding protein behaves as a potent pro-inflammatory
cytokine following its late release from activated or necrotic cells
[33, 34]. Indeed, it has been demonstrated that HMGB1
acts as a late mediator of sepsis and endotoxin lethality, is
increased in the plasma of septic patients and its blockade
improves survival of septic rodents [34–38]. Thus, although TLR
activation imparts higher sensitivity to cellular responses to C5a,
this positive modulatory effect appears to be counterbalanced by
modulation of the pro-inflammatory activities of C5a and HMGB1
through the simultaneous negative effect on C5aR and C5L2
respectively. In line with the regulatory mechanism postulated
here, it has been demonstrated that the combined blockade of
C5aR and C5L2 greatly improved survival in a mouse model of
severe sepsis [11].
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Figure 6. Effect of TLR activation on C5L2 receptor activity. (A) Western blot analysis and densitometric scanning of HMGB1 levels in cytoplasmic
cell extracts of PBMCs (0.5 106/condition) pre-exposed (14 h) or not to LPS (100 pg/mL) and subsequently activated (14 h) or not with C5a (10 nM).
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five. po0.05; po0.01; po0.005, paired Student’s t-test. (B) Western blot analysis and densitometric scanning of C5a (60 nM)-induced levels of
HMGB1 in culture supernatants of whole blood cells (100 mL whole blood/condition) from TLR4 signalling-deficient (C3H/HeJ) and WT mice (n5 5/
condition) challenged (1 h) i.p. with LPS (50 mg/mouse) or PBS (No LPS). Results shown for each condition are of the pooled supernatants of the five
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This study has also shed light on the mechanism underlying
the TLR modulatory effect. The TLR-mediated hypersensitivity to
C5a did not result from C5a receptor upregulation, as discussed
above. Furthermore, a TLR modulatory effect of similar intensity
was observed over a wide range of LPS concentrations
(0.1–1000 ng/mL, Fig. 1C). This, together with the observation
that a 30-min cell pre-exposure to LPS was sufficient to achieve
maximal hypersensitivity to C5a (Fig. 4A), suggested that
modulation did not result from a carryover effect of TLR-induced
cytokines. Consistent with this possibility, cells pre-exposed to
LPS and subsequently cultured in the absence of C5a did not
show activation of the transcription factor NF-kB – a key regu-
lator of cytokine/chemokine gene transcription – at the end of
the culture (Fig. 1F). This observation also indicated that the TLR
enhancing effect did not result from residual TLR ligands carried
over from the TLR activation phase.
The findings described previously, and the fact that TLR
modulation did not affect Ca21 mobilization, prompted us to test
whether a C5a-triggered G-protein-independent signalling event
was the primary target of TLR modulation. We therefore sought
to test the effect of TLR activation on the activity of the G protein-
uncoupled C5a receptor, C5L2. The reduced levels of C5a-
induced HMGB1 observed following cell pre-exposure to LPS in
vitro and ex vivo, and the LPS-mediated downregulation of C5L2
expression – although occurring indirectly upon subsequent C5a
stimulation – confirmed C5L2 as a target for negative modulation
by TLRs. In neutrophils, activation of C5L2 appears to occur only
as a consequence of C5aR activation [13]. If this was also the case
in monocytes, it may be speculated that the marked down-
regulation of C5aR expression induced by TLR activation
observed in this study contributes to the TLR negative modula-
tory effect on C5L2 activity. C5L2 was demonstrated to bind C5a
with high affinity, similar to that of C5aR. However, in contrast to
C5aR, it is unable to couple to intracellular G proteins and induce
Ca21 mobilization [26]. Consistent with these findings, it has
been demonstrated that C5L2 can act as a decoy or scavenger C5a
receptor, controlling C5aR activity [26–28]. It has also been
reported that C5L2 negatively modulates C5aR signalling by
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inhibiting C5aR-b-arrestin-mediated ERK1/2 activation [13]. In
contrast, a number of reports have demonstrated positive or dual
signalling functions of C5L2 [11, 12, 39, 40]. In particular, the
work by Rittirsch et al. [11] demonstrated that the absence of
C5L2 in mice subjected to cecal ligation and puncture (CLP)
resulted in decreased levels of IL-1b, MIP-1a, MIP-2 and HMGB1,
suggesting pro-inflammatory activity by C5L2. Notably, however,
the same work showed that in C5L2KO mice subjected to cecal
ligation and puncture, the levels of the pro-inflammatory cyto-
kine IL-6 were significantly increased. These findings suggest that
the mechanism regulating pro-inflammatory mediator release
involving C5L2 is complex and that the net result of C5L2 activity
may depend on the magnitude of the C5L2 modulatory effect on
each mediator affected and the relative contribution of that
mediator to the net resulting effect. In the present study, the
similarities between the effects of C5L2 receptor blockade and
those resulting from cell pre-exposure to LPS, and the lack of
response of C5L2KO mice to pre-exposure to LPS (no increased
sensitivity to C5a) led us to conclude that TLRs may enhance cell
sensitivity to C5a by regulating the negative modulatory capacity
of C5L2 on a number of pro-inflammatory mediators.
Notably, the C5a-stimulated blood cells from C5L2-deficient
mice that had not been challenged with LPS did not show
increased KC production. This was unexpected, as we speculated
that the absence of the putative negative regulator of C5aR,
C5L2, should result in increased cell sensitivity to C5a. It is
possible that an additional, compensatory, negative regulatory
mechanism controlling responses to C5a operates only in the
complete absence of C5L2 (C5L2KO mice). This would be
compatible with the increased sensitivity to C5a resulting from
C5L2 receptor inhibition by TLR activation or Ab blockade
observed in this study, as such a compensatory negative regula-
tory mechanism would not be operational due to the presence of
C5L2. In contrast to C5L2, the second regulatory mechanism
would not be susceptible to negative regulation by TLRs, as the
blood cells from C5L2KO mice pre-treated with LPS did not show
increased KC production (Fig. 7B, C5L2KO1LPS).
We observed that the degree of the TLR-induced enhancing
effect on cell sensitivity to C5a varies among individuals
(Fig. 2B). This may be due to the differing extent of the down-
modulatory effect exerted by TLRs on C5aR and C5L2 expression,
which may depend on the different constitutive expression levels
of these receptors in each individual. We also observed a decline
in most individuals’ response to TLR activation at higher
concentrations of C5a (Fig. 2B). It is possible that at higher C5a
concentrations, such as those that might be generated in vivo
during an acute infection, a more pronounced activation and
ligand-induced downregulation of C5aR may lead to C5L2
becoming comparatively more engaged. This may result in a
stronger negative modulatory effect on C5aR responses that
would counteract and limit the TLR enhancing effect. Thus, an
individual’s capacity to clear infections efficiently and success-
fully resolve inflammation might be determined, at least in part,
by the extent of the TLR enhancing effect relative to C5L2’s
capacity to counteract this positive effect.
In conclusion, the findings reported in this study demonstrate
the existence of an efficient immunomodulatory network involving
two major components of the innate immune system, TLRs and
complement. In particular, we show that the positive modulation
of TLR-mediated pro-inflammatory responses by complement
receptors reported previously is paralleled by an equally substan-
tial enhancing effect of TLRs on cell sensitivity to the pro-inflam-
matory peptide, C5a, through TLR negative modulation of the
C5aR activity regulator, C5L2. The description of the mutually
regulated and concerted activities of TLRs and complement in
innate host defense may help to identify new therapeutic targets to
control acute and chronic inflammatory conditions.
Materials and methods
Cell activations
Human blood samples were obtained from healthy volunteers as
approved by the local Research Ethics Committee. PBMCs were
obtained through Ficoll density-gradient centrifugation. For cell
activation experiments, triplicate cell aliquots (1.5105 cells/
well, unless stated otherwise) were cultured in RPMI 1640
medium (Invitrogen) supplemented with 10% heat-inactivated
(561C, 30min) FCS (HyClone;o0.06U/mL endotoxin) and 2mM
glutamine (complete medium), and stimulated at 371C for 14 h or
the time indicated with optimal concentrations of ultra-pure LPS
(E. coli O111:B4 strain), zymosan, flagellin, imiquimod – all from
Invivogen – Pam3-Cys-Ser-(Lys)4 HCl (Pam3Cys; EMC micro-
collections GmbH) as indicated, or medium alone (mock
stimulation). Following incubation, cells were washed (3 ,
RPMI 1640 medium), resuspended in complete medium and
activated for a further 12–14 h with the indicated concentrations
of human recombinant C5a (kindly provided by Dr P.N. Monk,
Sheffield University, UK) or mock activated. Cell culture super-
natants were then tested for IL-8 or IL-6 by ELISA (Duoset, R&D
Systems). For C5L2 receptor blocking experiments, PBMCs were
preincubated (30min at 371C) with the anti-human C5L2
blocking mAb, 1D9-M12 (5mg/mL; Biolegend), before stimula-
tion with C5a (2.5 nM). In control experiments, the 1D9-M12
mAb was denatured by boiling for 10min. For the experiments
shown in Fig. 2, triplicate samples of heparinized (10 IU/mL)
human whole blood (100 mL/well) were exposed for 14 h to LPS
(500 pg/mL) or heat-killed E. coli (O111:B4 strain, 1 108CFU/
mL). Subsequently, samples were centrifuged (300 g, 5min),
the blood cells washed (3, RPMI 1640 medium), resuspended
in heat-inactivated 100% autologous plasma and activated with
the indicated concentrations of C5a.
The C5a-induced IL-8 concentrations were estimated by
subtracting the background levels of IL-8 present in cultures not
activated with C5a and pre-exposed or not to TLR ligands from
the corresponding C5a-activated samples (background levels of
the experiments described in Fig. 1B – typical of all experiments
– are shown in the figure legend).
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Quantitative RT-PCR (RT-qPCR)
PBMCs (1 106 cells/condition) were cultured in complete
medium, stimulated or not with 100 pg/mL LPS, washed, and
activated with C5a (10 nM), as described above. RNA was phenol
extracted (Tri Reagent, Ambion) and reverse transcription was
performed using random primers (High Capacity cDNA Reverse
Transcription, Applied Biosystems). qPCR was performed on the
resulting cDNA using the Power SYBR Green PCR master
mix (Applied Biosystems) and specific primers (Invitrogen):
IL-6, 50-CAGTTCCTGCAGAAAAAGGC-30 and 50-GAATGAGAT-
GAGTTGTCATG-30; IL-8, 50-GAACTGAGAGTGATTGAGAGT
GGA-30 and 50-CTCTTCAAAAACTTCTCCACAACC-30; C5aR,
50-GGAGACCAGAACATGAACTC-30 and 50-ATCCACAGGGGTGTT-
GAGGT-30; b-glucuronidase, 50-TCTGTATTCATTGGAGGTGC-30
and 50-AAGGTTTCCCATTGATGAGG-30. PCR was carried out
using the ABI 7900HT real-time PCR system (Applied Biosys-
tems), and results were analyzed by the DDCt method [41].
NF-jB assays
PBMCs (1 107 cells/condition) were pre-exposed or not to
100 pg/mL LPS, washed and activated with C5a (10 nM) as
previously described. Nuclear extracts were prepared (Nuclear
Extract kit, Active Motif), and their protein concentration
determined (ProStain Fluorescent Protein Quantification, Active
Motif). Five micrograms of total protein/sample were used to
determine NF-kB p65 concentrations (ELISA, TransAM NF-kB
p65, Active Motif).
In vivo model of TLR activation
Inbred 8- to 12-wk-old C3H/HeN, C3H/HeJ (Harlan), BALB/c
(The Jackson Laboratory) and C5L2KO (on BALB/c background)
mice were maintained under barrier conditions and pathogen
free. All experimental procedures were carried out under Home
Office (UK) or the Ministerium fu¨r Landwirtschaft, Umwelt und
la¨ndliche Ra¨ume (Kiel, Germany) project licenses. Mice (n55/
condition) were i.p. injected with a previously defined dose of
LPS (50 mg/mouse) or phosphate-buffered saline (PBS). After 1 h,
blood was collected by cardiac puncture and samples (100mL/
condition) were washed (3, RPMI 1640), resuspended in
complete medium and stimulated (14 h) with the indicated
concentrations of mouse C5a (Hycult). The cell culture super-
natants were tested for KC and MCP-1 by ELISA (R&D Systems),
and for HMBG1 by Western blot.
C5aR cell-surface expression
PBMCs (1106/condition) or whole blood (100 mL/condition)
were stimulated (30min) with 100 pg/mL (PBMCs) or 500 pg/mL
(whole blood) LPS or mock stimulated. Following incubation, cell
aliquots were collected for C5aR expression analysis, and the
remaining samples were washed and activated or not with C5a
(10 nM) for the indicated times. At each time point, cell aliquots
were tested for C5aR cell-surface expression on gated monocytes
or neutrophils – identified by their CD141 staining and forward
and side scatter profiles – by flow cytometry using a human
C5aR-specific mAb (S5/1, Hycult), as described [42].
Ca21 mobilization assays
Ca21 mobilization in gated monocytes was analyzed by flow
cytometry, as described [43]. PBMCs (1106 cells/condition)
were activated or not with LPS for 30min or 14 h before
staining (30min, room temperature) with the Ca21-chelating
fluorescent dye Fluo3-AM (10 mM, Molecular Probes) or first
stained with Fluo3-AM before a 3-min activation with LPS. An
aliquot was taken from each sample for testing the background
fluorescence at time 0. C5a (10 nM) was subsequently added to
the remaining samples, and fluorescence was first measured 10 s
after addition of C5a, and thereafter every 30 s for a total of
3min. Results are expressed as normalized [Ca21]i, as a measure
of the fold increase in intracellular Ca21 concentration at each
time point after the addition of C5a, by determining the ratio
between the mean fluorescence intensity at time t and that at
time 0.
Western blots
HMGB1 and C5L2 levels in cytoplasmic preparations from PBMCs
and in culture supernatants (20 mL) of mouse blood cells
(HMGB1) were evaluated by Western blot analysis, as described
[44]. Here, PBMCs (0.5 106 cells/condition) were cultured with
or without LPS, washed and stimulated or not with C5a. Cells
were then lysed (0.5% v/v Nonidet P-40, 50mM Tris-HCl,
150mM NaCl, 1mg/mL leupeptin and pepstatin, 1mM PMSF,
pH 7.4 buffer) for 1 h on ice, and the protein content of the
cytoplasmic cell extracts was estimated (BCA assay, Bio-Rad).
HMGB1 and C5L2 were detected by using an anti-human and
mouse HMGB1-specific polyclonal Ab (Ab18256, Abcam) and the
anti-human C5L2 mAb 1D9-M12.
Statistical analysis
Statistical analysis of the data was performed by using a paired
Student’s t-test. p valueso0.05 were considered significant.
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